TY - JOUR T1 - In-silico, interactomic and clinical validation based approach for screening and identification of miR biomarkers involved in Oral submucous fibrosis to Oral squamous cell carcinoma transition JF - medRxiv DO - 10.1101/2020.10.05.20206904 SP - 2020.10.05.20206904 AU - Shweta Ukey AU - Jeewan Ram Vishnoi AU - Chinmayee Choudhury AU - Purvi Purohit AU - Shailendra Dwivedi AU - Ankit jain AU - Ankita Chugh AU - Poonam Elhence AU - Puneet Pareek AU - Sanjeev Misra AU - Praveen Sharma Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/08/2020.10.05.20206904.abstract N2 - Oral Squamous Cell Carcinoma (OSCC) is common preventable disease when diagnosed early, but mostly its progression follows transition from oral potentially malignant disorders (OPMDs) like Oral Submucous Fibrosis (OSF). However, it is difficult to predict possibilities of progression in these premalignant lesions hence, identification of molecular biomarkers would have major clinical impact in early diagnosis and better prognosis. In this context microRNA’s(miR’s) provide better opportunities in malignancy prediction and demarcation in OSF to OSCC transition as they perform key regulatory roles in many tumorigenic processes. Here, we computationally screened differentially expressed miR’s of OSCC and OSF from public databases followed by construction of protein interaction networks and enrichment analyses. The relevant miR’s were validated using qPCR of total 93 samplesincluding 34 OSCC, 30 OSF and 29 control blood and tissue samples. We identified significant down regulation of miR-133a-3p in OSCC compared to controls and interesting up-regulation compared to OSCC and control. miR-9-5p was up-regulated in OSF as well as OSCC and down-regulated in OSF compared to OSCC. Therefore, these two miR’s may serve as risk stratification biomarkers with validation in larger categorical datasets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAIIMS/RES(04)/2017/224Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional ethical committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yessupplimentary dataOSCCOral squamous cell carcinomaHNSCCHead and neck cancerOPMDsOral potentially malignant disordersOSFOral submucous fibrosisEMTEpithelial mesenchymal transitionHPVHuman papilloma virusmiR’smicroRNA’s ER -